News Novo Nordisk A/S Mexican S.E.

Equities

NVO N

US6701002056

End-of-day quote Mexican S.E. Other stock markets 03:30:00 28/06/2024 am IST			5-day change	1st Jan Change
2,631 ^MXN	-1.09%		+2.18%	+49.70%

28/06	India plans incentives for diabetes, obesity drug makers in 2026, government official says	RE
28/06	NOVO NORDISK : UBS gives a Neutral rating	ZD

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

India plans incentives for diabetes, obesity drug makers in 2026, government official says	28/06	RE
NOVO NORDISK : UBS gives a Neutral rating	28/06	ZD
European Equities Close Mostly Lower Thursday; Bank of England Warns of 'Sharp Correction' Risk	27/06	MT
Top Midday Stories: Walgreens Shares Tumble on Lower Guidance, Store Closures; SM Energy, NOG to Buy XCL Resources; Uber, Lyft Worker Classification Heads to Massachusetts Ballot	27/06	MT
Novo Nordisk to Limit Launch of Wegovy in China, Executive Says	27/06	MT
NOVO NORDISK : JP Morgan gives a Buy rating	27/06	ZD
The same old winners	27/06
NOVO NORDISK : Goldman Sachs reiterates its Buy rating	27/06	ZD
2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours	27/06	MT
2seventy Bio Sells Gene Editing Therapy To Novo Nordisk for Up To $40 Million	27/06	DJ
Sector Update: Health Care Stocks Softer Late Afternoon	27/06	MT
Sector Update: Health Care Stocks Lower in Afternoon Trading	27/06	MT
Sector Update: Health Care	27/06	MT
European Equities Close Lower in Wednesday Trading	26/06	MT
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment	26/06	MT
Novo Nordisk to Take $816.2 Million Impairment Loss After Stopping Clarion-CKD Trial	26/06	MT
Novo Nordisk Halts Late-stage Hypertension, Kidney Disease Treatment Trial; DKK6 Billion Impairment Loss Expected	26/06	MT
Novo Nordisk: trial failure and impact on results	26/06	CF
Novo Nordisk to Take $816.2 Million Impairment Loss After Stopping Clarion-CKD Trial	26/06	MT
Novo Nordisk to Take $816 Million Impairment Charge After Stopping Clarion-CKD Trial	26/06	MT